References

Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States

10.1001/jamanetworkopen.2021.24750 · ExternalCitation · doi-reference

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

10.1001/jamaoncol.2017.0589 · ExternalCitation · doi-reference

Association of a Prophylactic Surgical Approach to Stage IV Small Intestinal Neuroendocrine Tumors With Survival

10.1001/jamaoncol.2017.3326 · ExternalCitation · doi-reference

Recurrence in Resected Gastroenteropancreatic Neuroendocrine Tumors

10.1001/jamaoncol.2018.0024 · ExternalCitation · doi-reference

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms

10.1002/1097-0142(19910715)68:2<227::aid-cncr2820680202>3.0.co;2-i · ExternalCitation · doi-reference

Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit

10.1002/jso.25896 · ExternalCitation · doi-reference

Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide

10.1002/onco.13611 · ExternalCitation · doi-reference

Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 is ≥ 10%?

10.1002/onco.13633 · ExternalCitation · doi-reference

Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy

10.1007/s00259-010-1610-2 · ExternalCitation · doi-reference

Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN)-a single-institution retrospective analysis

10.1007/s00259-017-3821-2 · ExternalCitation · doi-reference

Postoperative Complications, In-Hospital Mortality and 5-Year Survival After Surgical Resection for Patients with a Pancreatic Neuroendocrine Tumor: A Systematic Review

10.1007/s00268-015-3328-6 · ExternalCitation · doi-reference

Evaluating Nationwide Application of Minimally Invasive Surgery for Treatment of Small Bowel Neuroendocrine Neoplasms

10.1007/s00268-021-06036-0 · ExternalCitation · doi-reference

Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience

10.1007/s00280-012-2055-z · ExternalCitation · doi-reference

Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms

10.1007/s00432-018-2636-2 · ExternalCitation · doi-reference

Surgical microwave ablation of 397 neuroendocrine liver metastases: A retrospective cohort analysis of 16 years of experience

10.1007/s00464-024-11021-4 · ExternalCitation · doi-reference

A novel risk factor panel predicts early recurrence in resected pancreatic neuroendocrine tumors

10.1007/s00535-021-01777-0 · ExternalCitation · doi-reference

JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: Diagnosis, treatment, and follow-up: A synopsis

10.1007/s00535-021-01827-7 · ExternalCitation · doi-reference

Chemotherapy in NEN: Still has a role?

10.1007/s11154-021-09638-0 · ExternalCitation · doi-reference

Role of fluorouracil, doxorubicin, and streptozocin therapy in the preoperative treatment of localized pancreatic neuroendocrine tumors

10.1007/s11605-016-3270-4 · ExternalCitation · doi-reference

Early Recurrence of Neuroendocrine Liver Metastasis After Curative Hepatectomy: Risk Factors, Prognosis, and Treatment

10.1007/s11605-017-3490-2 · ExternalCitation · doi-reference

Surgery Provides Long-Term Survival in Patients with Metastatic Neuroendocrine Tumors Undergoing Resection for Non-Hormonal Symptoms

10.1007/s11605-018-3986-4 · ExternalCitation · doi-reference

A Prognostic Scoring System for the Prediction of Metastatic Recurrence Following Curative Resection of Pancreatic Neuroendocrine Tumors

10.1007/s11605-018-4011-7 · ExternalCitation · doi-reference

Surgery in patients with gastro-entero-pancreatic neuroendocrine carcinomas, neuroendocrine tumors G3 and high grade mixed neuroendocrine-non-neuroendocrine neoplasms

10.1007/s11864-022-00969-x · ExternalCitation · doi-reference

Radionuclide therapy for neuroendocrine tumors

10.1007/s11912-017-0567-8 · ExternalCitation · doi-reference

Histopathological and Immunophenotypic Changes of Pancreatic Neuroendocrine Tumors after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT)

10.1007/s12022-020-09623-4 · ExternalCitation · doi-reference

Treatment of high-grade metastatic pancreatic neuroendocrine carcinoma with FOLFIRINOX

10.1007/s12029-015-9689-0 · ExternalCitation · doi-reference

Predictors of post-operative pancreatic fistula formation in pancreatic neuroendocrine tumors: A national surgical quality improvement program analysis

10.1016/j.amjsurg.2022.07.007 · ExternalCitation · doi-reference

Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

10.1016/j.annonc.2020.03.304 · ExternalCitation · doi-reference

1157O A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)

10.1016/j.annonc.2020.08.1370 · ExternalCitation · doi-reference

1098O Nivolumab plus platinum-doublet chemotherapy as first-line therapy in unresectable, locally advanced or metastatic G3 neuroendocrine Neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or unknown (UK) origin: Preliminary results from the phase II NICE-NEC trial (GETNE T1913)

10.1016/j.annonc.2021.08.180 · ExternalCitation · doi-reference

496MO Final overall survival results from the NICE-NEC trial (GETNE-T1913): A phase II study of nivolumab and platinum-doublet chemotherapy (CT) in untreated advanced G3 neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) or unknown (UK) origin

10.1016/j.annonc.2022.07.624 · ExternalCitation · doi-reference

Gastroenteropancreatic neuroendocrine neoplasms G3: Novel insights and unmet needs

10.1016/j.bbcan.2021.188637 · ExternalCitation · doi-reference

Management of Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): A Review

10.1016/j.clinthera.2017.10.010 · ExternalCitation · doi-reference

Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): A randomized clinical trial

10.1016/j.esmoop.2025.105922 · ExternalCitation · doi-reference

Short- and long-term outcomes after enucleation of pancreatic tumors: An evidence-based assessment

10.1016/j.pan.2016.07.006 · ExternalCitation · doi-reference

Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after resection of liver metastases from digestive endocrine tumors?

10.1016/j.surg.2008.08.007 · ExternalCitation · doi-reference

Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms

10.1016/j.surg.2017.11.007 · ExternalCitation · doi-reference

Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs)

10.1016/j.surg.2018.04.070 · ExternalCitation · doi-reference

Margin status and long-term prognosis of primary pancreatic neuroendocrine tumor after curative resection: Results from the US Neuroendocrine Tumor Study Group

10.1016/j.surg.2018.08.015 · ExternalCitation · doi-reference

Repeat hepatectomy for patients with recurrent neuroendocrine liver metastasis: Comparison with first hepatectomy

10.1016/j.surg.2019.08.020 · ExternalCitation · doi-reference

Evaluating the role of postoperative long-acting somatostatin analog therapy in patients with metastatic neuroendocrine tumors undergoing surgical debulking

10.1016/j.surg.2025.109762 · ExternalCitation · doi-reference

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study

10.1016/s0140-6736(11)61742-x · ExternalCitation · doi-reference

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study

10.1016/s0140-6736(15)00817-x · ExternalCitation · doi-reference

[(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): An open-label, randomised, phase 3 study

10.1016/s0140-6736(24)00701-3 · ExternalCitation · doi-reference

[(177)Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): A phase 3, multicentre, randomised, open-label, superiority trial

10.1016/s0140-6736(26)00604-5 · ExternalCitation · doi-reference

Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: Joint analysis of two prospective, non-randomised trials

10.1038/s41416-020-0775-0 · ExternalCitation · doi-reference

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin

10.1038/sj.bjc.6690325 · ExternalCitation · doi-reference

Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors

10.1055/a-1908-7790 · ExternalCitation · doi-reference

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

10.1056/nejmoa1003825 · ExternalCitation · doi-reference

Everolimus for advanced pancreatic neuroendocrine tumors

10.1056/nejmoa1009290 · ExternalCitation · doi-reference

Lanreotide in metastatic enteropancreatic neuroendocrine tumors

10.1056/nejmoa1316158 · ExternalCitation · doi-reference

Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors

10.1056/nejmoa1607427 · ExternalCitation · doi-reference

Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms

10.1080/0284186x.2021.1921262 · ExternalCitation · doi-reference

Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: Final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study

10.1093/annonc/mdx193 · ExternalCitation · doi-reference

COMPETE trial: Peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide vs. everolimus in progressive GEP-NET

10.1093/annonc/mdy293.028 · ExternalCitation · doi-reference

Pancreatic neuroendocrine tumours: Conservative versus surgical management

10.1093/bjs/znab232 · ExternalCitation · doi-reference

Surgery for advanced pancreatic neuroendocrine neoplasms: Recommendations based on a consensus meeting of the European Society of Endocrine Surgeons (ESES)

10.1093/bjs/znae017 · ExternalCitation · doi-reference

Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): Multicentre phase II study

10.1093/bjs/znae178 · ExternalCitation · doi-reference

The effect of using long-acting octreotide as adjuvant therapy for patients with grade 2 pancreatic neuroendocrine tumors after radical resection

10.1097/jp9.0000000000000058 · ExternalCitation · doi-reference

Everolimus in pancreatic neuroendocrine carcinomas G3

10.1097/mpa.0000000000000762 · ExternalCitation · doi-reference

The surgical management of small bowel neuroendocrine tumors: Consensus guidelines of the North American Neuroendocrine Tumor Society

10.1097/mpa.0000000000000846 · ExternalCitation · doi-reference

The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors

10.1097/mpa.0000000000001454 · ExternalCitation · doi-reference

Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors

10.1097/mpa.0000000000001500 · ExternalCitation · doi-reference

Efficacy and Toxicity of 5-Fluorouracil-Oxaliplatin in Gastroenteropancreatic Neuroendocrine Neoplasms

10.1097/mpa.0000000000001593 · ExternalCitation · doi-reference

Therapeutic Efficacy of Neoadjuvant Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors: A Meta-analysis

10.1097/rlu.0000000000006276 · ExternalCitation · doi-reference

A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients

10.1097/sla.0000000000003461 · ExternalCitation · doi-reference

Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: A critical appraisal of 48 cases

10.1097/sla.0b013e3181d3d24a · ExternalCitation · doi-reference

Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): Guidelines from the NET-Liver-Metastases Consensus Conference

10.1111/hpb.12326 · ExternalCitation · doi-reference

Postoperative morbidity and mortality after surgical resection of small bowel neuroendocrine neoplasms: A systematic review and meta-analysis

10.1111/jne.13008 · ExternalCitation · doi-reference

Real-world effectiveness of adjuvant octreotide therapy in patients with pancreatic neuroendocrine tumors at high recurrence risk: A multicenter retrospective cohort study

10.1111/jne.13442 · ExternalCitation · doi-reference

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study

10.1158/1078-0432.ccr-19-3014 · ExternalCitation · doi-reference

ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: Functional pancreatic endocrine tumor syndromes

10.1159/000335591 · ExternalCitation · doi-reference

ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas

10.1159/000443172 · ExternalCitation · doi-reference

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors

10.1159/000461583 · ExternalCitation · doi-reference

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms. Systemic Therapy 2: Chemotherapy

10.1159/000473892 · ExternalCitation · doi-reference

Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses

10.1159/000498887 · ExternalCitation · doi-reference

The Role of Perioperative Systemic Therapy in Localized Pancreatic Neuroendocrine Neoplasms

10.1159/000501126 · ExternalCitation · doi-reference

Capecitabine-Temozolomide in Advanced Grade 2 and Grade 3 Neuroendocrine Neoplasms: Benefits of Chemotherapy in Neuroendocrine Neoplasms with Significant 18FDG Uptake

10.1159/000511987 · ExternalCitation · doi-reference

Multimodality management of “borderline resectable” pancreatic neuroendocrine tumors: Report of a single-institution experience

10.1177/1073274817729076 · ExternalCitation · doi-reference

10.1186/s12885-025-15111-x

10.1186/s12885-025-15111-x · ExternalCitation · doi-reference

Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: A nomogram-based study

10.1186/s12957-017-1169-5 · ExternalCitation · doi-reference

A case of successful conversion from everolimus to surgical resection of a giant pancreatic neuroendocrine tumor

10.1186/s40792-017-0361-8 · ExternalCitation · doi-reference

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas

10.1200/jco.2004.04.024 · ExternalCitation · doi-reference

Effective treatment of neuroendocrine tumors with temozolomide and capecitabine

10.1200/jco.2005.23.16_suppl.4216 · ExternalCitation · doi-reference

One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

10.1200/jco.2007.15.4377 · ExternalCitation · doi-reference

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group

10.1200/jco.2009.22.8510 · ExternalCitation · doi-reference

Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors

10.1200/jco.2011.40.3147 · ExternalCitation · doi-reference

Efficacy of somatostatin analog (SSA) monotherapy for well-differentiated grade 3 (G3) gastroenteropancreatic neuroendocrine tumors (NETs)

10.1200/jco.2020.38.4_suppl.617 · ExternalCitation · doi-reference

Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)

10.1200/jco.22.01013 · ExternalCitation · doi-reference

Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline

10.1200/jco.23.01529 · ExternalCitation · doi-reference

Advances in the Treatment of Gastroenteropancreatic Neuroendocrine Carcinomas: Are we Moving Forward?

10.1210/endrev/bnad006 · ExternalCitation · doi-reference

Meta-analysis of Liver Resection Versus Nonsurgical Treatments for Pancreatic Neuroendocrine Tumors with Liver Metastases

10.1245/s10434-015-4654-5 · ExternalCitation · doi-reference

Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?

10.1245/s10434-019-08049-5 · ExternalCitation · doi-reference

Radical Resection in Entero-Pancreatic Neuroendocrine Tumors: Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence

10.1245/s10434-022-11837-1 · ExternalCitation · doi-reference

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

10.1245/s10434-022-12906-1 · ExternalCitation · doi-reference

Survival and Symptomatic Relief After Cytoreductive Hepatectomy for Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 Patients

10.1245/s10434-023-13372-z · ExternalCitation · doi-reference

Peptide Receptor Radionuclide Therapy Improves Survival in Patients Who Progress After Resection of Gastroenteropancreatic Neuroendocrine Tumors

10.1245/s10434-024-16463-7 · ExternalCitation · doi-reference

Surgery for Gastroenteropancreatic Neuroendocrine Tumors with Synchronous Liver Metastasis

10.1245/s10434-025-18409-z · ExternalCitation · doi-reference

FOLFIRI regimen: An effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3

10.1530/erc-12-0002 · ExternalCitation · doi-reference

Neuroendocrine tumor disease: An evolving landscape

10.1530/erc-12-0024 · ExternalCitation · doi-reference

Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: A multicenter cohort study

10.1530/erc-18-0424 · ExternalCitation · doi-reference

PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3)

10.1530/erc-19-0400 · ExternalCitation · doi-reference

Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms

10.1530/erc-22-0206 · ExternalCitation · doi-reference

10.18103/mra.v13i2.6309

10.18103/mra.v13i2.6309 · ExternalCitation · doi-reference

A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocrine neoplasms in china

10.18632/oncotarget.17599 · ExternalCitation · doi-reference

Radioembolization for neuroendocrine liver metastases is safe and effective prior to major hepatic resection

10.21037/hbsn.2019.07.11 · ExternalCitation · doi-reference

Neuroendocrine liver metastases: A contemporary review of treatment strategies

10.21037/hbsn.2020.04.02 · ExternalCitation · doi-reference

Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate

10.2967/jnumed.115.158899 · ExternalCitation · doi-reference

Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant (177)Lu-DOTATATE PRRT for Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Tumors

10.2967/jnumed.120.258772 · ExternalCitation · doi-reference

10.3390/cancers11091395

10.3390/cancers11091395 · ExternalCitation · doi-reference

10.3390/cancers17091561

10.3390/cancers17091561 · ExternalCitation · doi-reference

10.3390/jcm12155138

10.3390/jcm12155138 · ExternalCitation · doi-reference

Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management

10.3748/wjg.v26.i19.2305 · ExternalCitation · doi-reference

Efficacy and safety of neoadjuvant therapy in gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis

10.4103/jcrt.jcrt_1800_23 · ExternalCitation · doi-reference

Clinicopathological and survival features of neuroendocrine tumors: A retrospective analysis of 153 cases, our current remarks on a heterogeneous tumor group, and still unmet future expectations

10.4103/jcrt.jcrt_353_22 · ExternalCitation · doi-reference

Role of ablation therapy in conjunction with surgical resection for neuroendocrine tumors involving the liver

10.4240/wjgs.v16.i3.768 · ExternalCitation · doi-reference

Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

10.6004/jnccn.2021.0032 · ExternalCitation · doi-reference